Combines Synopsis Solicitation- NULISAseq Inflamma
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026Q01133 in this department, oldest first.
- Sep 2, 2026 · this noticeCombined Synopsis/Solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01133 and the solicitation is issued as a Notice of Intent (NOI) of a non-competitive (notice of intent) combined synopsis solicitation to award a contract or purchase order without providing for full or open competition (including brand-name)… (show all)
. This acquisition is conducted under the authority of the FAR Part 12.603� Streamlined solicitation for commercial products or commercial services, and is not expected to exceed the simplified acquisition threshold, and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-3(a)(2)(ii).
Who won similar work
11 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) Q301.
Single-winner award sizes (11): middle half $70K to $297K, median $157K; range $27K to $35.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AZENTA US INC | 1 | $35.0M | Dec 2, 2024 |
| PSOMAGEN INC | 1 | $533K | Dec 31, 2024 |
| NEW YORK STEM CELL FOUNDATION INC | 1 | $362K | Sep 23, 2025 |
| BAYLOR MIRACA GENETICS LABORATORIES LLC | 1 | $232K | Sep 26, 2025 |
| THE BROAD INSTITUTE, INC | 1 | $215K | Sep 29, 2026 |
| NORGEN BIOTEK CORP | 1 | $157K | Sep 19, 2025 |
| KAISER FOUNDATION HOSPITALS 1 KAISER PLAZA 22ND FLOOR Oakland CA 94612 USA | 1 | $115K | Sep 22, 2025 |
| ProteinTech Group Inc | 1 | $90K | Sep 19, 2025 |
| GREENWOOD GENETIC CENTER INC | 1 | $49K | Sep 25, 2025 |
| HISTOSERV, INC | 1 | $29K | May 5, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- Sep 29, 2026THE BROAD INSTITUTE, INC$215KWhole genome sequencing for investigation of age-related chronic disease in HANDLS participantsNo listed company matched (Materiality N/A)
- Sep 26, 2025BAYLOR MIRACA GENETICS LABORATORIES LLC$232KQ--Clinical TestingNo listed company matched (Materiality N/A)
- Sep 25, 2025GREENWOOD GENETIC CENTER INC$49KQ--Genetic Testing with Greenwood Genetic Center IncNo listed company matched (Materiality N/A)
- Sep 23, 2025NEW YORK STEM CELL FOUNDATION INC$362KQ--iPSC Generation and Beta Cell DifferentiationNo listed company matched (Materiality N/A)
- Sep 22, 2025KAISER FOUNDATION HOSPITALS 1 KAISER PLAZA 22ND FLOOR Oakland CA 94612 USA$115KQ--Adherence with continuous positive airwayNo listed company matched (Materiality N/A)
- Sep 19, 2025NORGEN BIOTEK CORP$157KQ--Small RNA characterization of urinary exosomesNo listed company matched (Materiality N/A)
- Sep 19, 2025ProteinTech Group Inc$90KCRO Services for Single-Cell Multiomics ProfilingNo listed company matched (Materiality N/A)
- Jul 24, 2025ADVANCED CELL DIAGNOSTICS, INC.$27KQ--RNAscope In-House AssayMateriality: <0.01% of $TECH revenue (Low) SEC
- May 5, 2025HISTOSERV, INC$29KSignatures of aging outcomesNo listed company matched (Materiality N/A)
- Dec 31, 2024PSOMAGEN INC$533KLong read sequencing servicesNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (8 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 5 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.